Infant formula occupies a regulatory position unlike any other food, because for some infants it is the sole source of nutrition. The rules reflect that dependence.
Nutrient content is specified in statute
Federal law sets minimum amounts for a list of required nutrients and maximum amounts for many of them, rather than leaving composition to the manufacturer.
Both bounds matter. A deficiency causes obvious harm, but excess of certain nutrients is also harmful to an infant whose kidneys and liver are still developing.
Any manufacturer wishing to deviate, or to market a formula for a specific medical condition, works within a defined exemption category rather than simply reformulating.
Notification precedes marketing
A new formula, or a major change to an existing one, must be notified to the regulator before it may be sold, with data supporting nutrient content and quality factors.
Quality factors include demonstrating that the protein is of sufficient biological quality and that infants fed the formula show normal physical growth.
The submission also covers manufacturing controls, since a nutrient specification is meaningless unless the process reliably produces what the specification describes.
Manufacturing controls are unusually prescriptive
Producers must test each batch for required nutrients, maintain records, and audit their processes, with specific requirements around microbiological testing.
Powdered formula cannot be sterilized in the container the way a liquid can, so contamination control depends on the process and the environment rather than on a terminal kill step.
Recall procedures are similarly specified, requiring the manufacturer to have a plan capable of retrieving product quickly through the distribution chain.
The compliance burden concentrates the market
Meeting the specification, the notification requirement and the manufacturing standards demands capital and technical capacity that few firms possess.
The result is a category supplied by a small number of large producers with a limited number of plants, which is a direct consequence of the regulatory design.
That concentration is also a fragility. A single plant halting production removes a meaningful share of national supply, and alternative capacity cannot be created quickly.
Where parents need a clinician rather than a label
Formulas marketed for allergy, prematurity, reflux or metabolic conditions exist as distinct regulated categories, and choosing among them is a clinical decision.
Diluting formula, substituting other milks, or preparing homemade formula introduces serious risk to an infant, and any question about feeding an infant who is not growing or tolerating a formula belongs with a pediatrician.